SG11202113132YA - Anti-gal9 immune-inhibiting binding molecules - Google Patents

Anti-gal9 immune-inhibiting binding molecules

Info

Publication number
SG11202113132YA
SG11202113132YA SG11202113132YA SG11202113132YA SG11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA SG 11202113132Y A SG11202113132Y A SG 11202113132YA
Authority
SG
Singapore
Prior art keywords
gal9
immune
binding molecules
inhibiting binding
inhibiting
Prior art date
Application number
SG11202113132YA
Inventor
Michelle Wykes
Dileep K Pulukkunat
Original Assignee
Council Queensland Inst Medical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Queensland Inst Medical Res filed Critical Council Queensland Inst Medical Res
Publication of SG11202113132YA publication Critical patent/SG11202113132YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202113132YA 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules SG11202113132YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US201962900105P 2019-09-13 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Publications (1)

Publication Number Publication Date
SG11202113132YA true SG11202113132YA (en) 2021-12-30

Family

ID=73552467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113132YA SG11202113132YA (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Country Status (10)

Country Link
US (1) US20220227873A1 (en)
EP (1) EP3976102A4 (en)
JP (1) JP2022534433A (en)
KR (1) KR20220030934A (en)
CN (1) CN114025797A (en)
AU (1) AU2020285369A1 (en)
CA (1) CA3141640A1 (en)
IL (1) IL288561A (en)
SG (1) SG11202113132YA (en)
WO (1) WO2020237320A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023220626A2 (en) * 2022-05-13 2023-11-16 Exelixis, Inc. 5t4 binding agents and uses thereof
WO2024159059A1 (en) * 2023-01-27 2024-08-02 Exelixis, Inc. Nkg2a binding agents and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511085A1 (en) * 1993-03-05 1994-09-15 Universite Catholique De Louvain Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003033709A2 (en) * 2001-10-17 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
KR101899835B1 (en) * 2010-03-24 2018-09-19 제넨테크, 인크. Anti-lrp6 antibodies
CN106999548A (en) * 2014-07-14 2017-08-01 昆士兰医学研究所理事会 galactose agglutinin immunotherapy
EP3625263A4 (en) * 2017-10-27 2021-05-05 New York University Anti-galectin-9 antibodies and uses thereof

Also Published As

Publication number Publication date
CN114025797A (en) 2022-02-08
AU2020285369A1 (en) 2021-12-23
CA3141640A1 (en) 2020-12-03
IL288561A (en) 2022-02-01
WO2020237320A1 (en) 2020-12-03
EP3976102A4 (en) 2023-07-12
JP2022534433A (en) 2022-07-29
EP3976102A1 (en) 2022-04-06
KR20220030934A (en) 2022-03-11
US20220227873A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
IL273631A (en) Hpv-specific binding molecules
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
IL289867A (en) Immunostimulatory multimeric binding molecules
GB201612520D0 (en) Binding molecules
GB201901306D0 (en) Multi-domain binding molecules
IL287555A (en) Binding molecules
GB201702091D0 (en) Specific binding molecules
GB201901305D0 (en) Specific binding molecules
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
IL289415A (en) Claudin-6 binding molecules and uses thereof
GB201811410D0 (en) OX40 Binding molecules
IL286013A (en) Cd3 binding molecules
IL289266A (en) Novel molecules
GB201811408D0 (en) CD137 Binding Molecules
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
GB201915282D0 (en) Specific binding molecules
EP3781204A4 (en) Binding molecules
IL269752B (en) Fgfr3 binding molecules
IL288562A (en) Activating anti-gal9 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
GB202006629D0 (en) Specific binding molecules
GB201912657D0 (en) Binding members
GB201914468D0 (en) Binding Molecules